Aratana Highlights Safety and Efficacy Data for Pet Therapeutics Programs at ACVIM

Aratana Therapeutics, Inc., a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, shared findings from the company’s ongoing development programs at the 2015 American College of Veterinary Internal Medicine (ACVIM) Forum. Aratana highlighted safety and efficacy data for pet therapeutics programs in cancer immunotherapy, pain and inappetence.

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, stated, “We are proud to have such a significant presence at ACVIM this year as we continue to broaden our therapeutic portfolio to address the unmet and underserved needs of veterinarians”. Data and observational studies resulting from the company’s extensive clinical development pipeline was featured in multiple oral and poster presentations during the conference. We also introduced the Aratana Scientific Library, a simple, efficient approach to sharing scientific and educational tools with the veterinary community.

A summary of presentations and posters shared at ACVIM are listed below. Visit all Aratana research at 

Cancer Therapies and Studies

  • The Evolving Science of Immunotherapeutics in Veterinary Oncology, Philip J. Bergman, DVM, Ph.D., DACVIM (Oncology); and Chad Johannes, DVM, DACVIM (SAIM, Oncology)
  • Clinical Application of Immunotherapeutics in Veterinary Oncology, Philip J. Bergman, DVM, Ph.D., DACVIM (Oncology); and Chad Johannes, DVM, DACVIM (SAIM, Oncology)
  • A Prospective, Open-Label Study Evaluating Treatment of Canine B-cell Lymphoma with L-Asparaginase, Doxorubicin and a Canine Anti-CD20 Monoclonal Antibody, Carlos O. Rodriguez, Jr., DVM, Ph.D., DACVIM (Oncology)
  • Anti-CD20 Monoclonal Antibody Canine Lymphoma Therapy: A Double-Blind, Randomized, Placebo-Controlled Study, Gregory Ogilvie, DACVIM (SAIM, Oncology), DECVIM-CA (Oncology)
  • Combination Listeria-Based Immunotherapy Plus Palliative Radiation Delays Tumor Progression and Prolongs Overall Survival in Canine Osteosarcoma, Nicola Mason, BVetMed, Ph.D., DACVIM (SAIM)

Inappetence Solutions in Development

  • Safety of the Ghrelin Agonist, Capromorelin, Administered Daily to Beagle Dogs for One Year, Linda Rhodes, VMD, Ph.D.
  • Capromorelin, An Orally Active Ghrelin Agonist, Caused Sustained Increases in IGF-1, Increased Food Intake and Body Weight in Cats, Bill Zollers, Ph.D.
  • Safety of the Ghrelin Agonist, Capromorelin, Administered to Cats for 91 Days at an Oral Dose of 6 mg/kg, Julie Allen, BVMS, MS, MRCVS, DACVIM (SAIM)
  • New Therapeutic Advances in Inappetence for Pets, Audrey Cook, BVM&S, MRCVS, DACVIM, (SAIM), DECVIM (CA), DABVP (Feline); and Julie Allen, BVMS, MS, MRCVS, DACVIM (SAIM)

Pain management Treatment Advances

  • Introduction to the Emerging Piprant Therapeutic Class of Prostanoid Receptor Antagonists, Kristin Kirkby Shaw, DVM, MS, Ph.D., DACVS, DACVSMR
  • Safety and Toxicokinetic Profiles in Cats Administered Grapiprant, A Selective Prostaglandin-Receptor Antagonist, Lesley Rausch-Derra, DVM, MS

The ACVIM Forum attracts more than 3,300 veterinary specialists in the field of internal medicine, general practitioners, and veterinary technicians from around the world, and focuses significantly on exploring the latest cutting-edge developments in pet therapeutics.


Recent News Posts

View All